Özlem ÖNER, Vildan Avkan OĞUZ, Mehmet Çağatay GÜRKOK, Mehmet Nuri YAKAR, Begüm ERGAN, Volkan HANCI, Erdem YAKA, Ali Necati GÖKMEN
Türk Yoğun Bakım Dergisi - 2026;24(1):30-39
Objective: During the pandemic, molnupiravir and favipiravir treatments have been applied at different stages of the treatment of COVID-19 patients. However, their effectiveness in COVID-19 patients admitted to the ICU is not clear. Methods: Patients who were admitted to the ICU between March 1, 2022, and December 31, 2023 and managed according to the guidelines of the Scientific Committee of the Turkish Ministry of Health were included. Results: Data of 152 patients who met the inclusion criteria for the study were evaluated. Patients were divided into two groups according to the treatment modality applied. When both groups were compared in terms of median hospital stay; It was found to be statistically significant (p=0.025) in Group F and 16 (11) days in Group M. When respiratory support was examined in the entire cohort; the percentage of invasive mechanical ventilation application was found to be significant as 40 (60.5) in Group F and 61 (80.3) in Group M (p=0.008). Similarly, the number of days of invasive mechanical ventilation was found to be significant as 9 (14) in Group F and 12 (8) in Group M (p=0.010). On the other hand, when evaluated in terms of hospital mortality percentage; it was found to be 42 (55.3) in Group F and 39 (51.3) in Group M and no statistically significant difference was found (p=0.626). Conclusion: In our study, no difference was found in terms of mortality rate between molnupiravir and favipiravir, two antiviral drugs used in COVID-19 treatment. However, further studies are needed to clarify this issue.
